EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients

Romain-David Seban, Laurence Champion, Audrey Bellesoeur, Anne Vincent-Salomon, Francois-Clement Bidard

Journal of Nuclear Medicine · 2023

DOI: 10.2967/jnumed.123.265434 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Romain-David Seban und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TO THE EDITOR: We have read with great interest the results of the DESTINY-Breast04 trial, “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer,” from Modi et al. and published in The New England Journal of Medicine ([1][1]). These impressive findings have also earned a

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmunoconjugatesHumansFemaleTrastuzumabCamptothecinBiomarkersPositron-Emission TomographyErb-b2 Receptor Tyrosine Kinases

Substanzen

TrastuzumabCamptothecinImmunoconjugatesBiomarkersErb-b2 Receptor Tyrosine Kinasestrastuzumab deruxtecan

Zitieren

APA

Seban, R. D., Champion, L., Bellesoeur, A., Vincent-Salomon, A., & Bidard, F. C. (2023). Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.265434

Vancouver

Seban RD, Champion L, Bellesoeur A, Vincent-Salomon A, Bidard FC. Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.265434

BibTeX
@article{Seban2023,
  author = {Seban, Romain-David and Champion, Laurence and Bellesoeur, Audrey and Vincent-Salomon, Anne and Bidard, Francois-Clement},
  title = {Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  doi = {10.2967/jnumed.123.265434}
}
Kostenlos starten →